The importance of MUC1 cellular localization in patients with breast carcinoma

The MUC1 mucin is present on the apical surface of normal secretory epithelia. In breast carcinoma, MUC1 expression is variable in amount and cellular localization, the significance of which is controversial. The authors undertook a detailed analysis of staining pattern combined with a comprehensive literature review to better understand the role of MUC1 in breast carcinoma.

[1]  V. Apostolopoulos,et al.  MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines , 2000, Cancer Immunology, Immunotherapy.

[2]  C. Musselli,et al.  Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. , 1999, Vaccine.

[3]  T. Eberlein,et al.  Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T‐cell activation , 1999, International journal of cancer.

[4]  J. Chu,et al.  Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast. , 1999, Cancer letters.

[5]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[6]  B. Sandmaier,et al.  Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. , 1999, Journal of immunotherapy.

[7]  D. Kufe,et al.  Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin , 1998, Molecular and Cellular Biology.

[8]  J. Hugh,et al.  MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. , 1998, Cancer research.

[9]  B. Longenecker,et al.  Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. , 1998, Cancer research.

[10]  B. Longenecker,et al.  The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. , 1998, Molecular medicine today.

[11]  A. Harris,et al.  MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. , 1998, Journal of clinical pathology.

[12]  M. Reddish,et al.  Immunogenicity and antitumor activity of a liposomal MUC1 peptide‐based vaccine , 1998, International journal of cancer.

[13]  D. Kufe,et al.  Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. , 1998, Molecular and cellular biology.

[14]  L. Pilarski,et al.  The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. , 1996, Cancer research.

[15]  K. Lloyd,et al.  Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. , 1996, Cancer research.

[16]  J. Wesseling,et al.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.

[17]  J. Taylor‐Papadimitriou,et al.  The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine , 1996, Cancer Immunology, Immunotherapy.

[18]  S. Gendler,et al.  The epithelial mucin, MUC1, of milk, mammary gland and other tissues. , 1995, Biochimica et biophysica acta.

[19]  D. Kufe,et al.  Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. , 1995, Cancer research.

[20]  Walsh,et al.  Prognostic significance of MUC1 epithelial mucin expression in breast cancer. , 1995, Human pathology.

[21]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[22]  P. Horgan,et al.  An evaluation of the usefulness of primary tumour expression of MCA and CA15-3 as prognostic indicators in breast carcinoma. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  R. Ceriani,et al.  Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE‐3 in breast‐cancer prognosis , 1992, International journal of cancer.

[24]  N. Peat,et al.  Structure and biology of a carcinoma-associated mucin, MUC1. , 1991, The American review of respiratory disease.

[25]  W Wood,et al.  Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  I. McKenzie,et al.  The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. , 1991, British journal of cancer.

[27]  R. Walker,et al.  Assessment of milk fat globule membrane antibodies and lectins as markers of short-term prognosis in breast cancer. , 1990, British Journal of Cancer.

[28]  A. J. Robertson,et al.  Critical evaluation of monoclonal antibody staining in breast carcinoma. , 1989, Journal of clinical pathology.

[29]  A. Howell,et al.  The expression of milk fat globule antigens within human mammary tumours: relationship to steroid hormone receptors and response to endocrine treatment. , 1989, European journal of cancer & clinical oncology.

[30]  I. Ellis,et al.  Monoclonal antibody NCRC 11 reactivity with advanced breast carcinoma: lack of prognostic value , 1988, Histopathology.

[31]  A. J. Robertson,et al.  Quantitation of human milk fat globule (HMFG1) expression in breast carcinoma and its association with survival. , 1988, Journal of Clinical Pathology.

[32]  J. Antonen,et al.  Human milk fat globule antigen III D 5, steroid receptors and histopathologic parameters in breast cancer , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[33]  B. Angus,et al.  Prognostic factors in breast cancer: Immunohistochemical staining for SP1 and NCRC 11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status , 1987, The Journal of pathology.

[34]  R. W. Baldwin,et al.  Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. , 1987, British Journal of Cancer.

[35]  M. Merino,et al.  Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. , 1987, Journal of the National Cancer Institute.

[36]  M. Helle.  The prognostic significance of the monoclonal antibody III D 5 to human milk fat globule antigen in breast cancer. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[37]  K. Krohn,et al.  Recognition with a monoclonal antibody of a cytoplasmic mammary carcinoma antigen, correlated to the estrogen receptor status , 1986, International journal of cancer.

[38]  I. Ellis,et al.  Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11. , 1986, The Journal of pathology.

[39]  R. W. Baldwin,et al.  Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. , 1985, British medical journal.

[40]  B. V. Pedersen,et al.  Prognostic value of surface antigens in primary human breast carcinomas, detected by monoclonal antibodies. , 1985, Cancer research.

[41]  J. Taylor‐Papadimitriou,et al.  The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. , 1985, British Journal of Cancer.

[42]  A. Howell,et al.  The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas , 1984, International journal of cancer.